Elucidation/NN
of/IN
the/DT
Inhibitory/JJ
Effect/JJ
of/IN
Phytochemicals/NNS
with/IN
Kir6.2/NN
Wild-Type/JJ
and/CC
Mutant/JJ
Models/NNS
Associated/VBN
in/IN
Type-1/NN
Diabetes/NNS
through/IN
Molecular/JJ
Docking/JJ
Approach/NN
./.
====================
Among/IN
all/DT
serious/JJ
diseases/NNS
globally/RB
,/,
diabetes/VBZ
(/(
type/NN
1/CD
and/CC
type/NN
2/CD
)/)
still/RB
poses/VBZ
a/DT
major/JJ
challenge/NN
to/TO
the/DT
world/NN
population/NN
./.
====================
Several/JJ
target/NN
proteins/NNS
have/VBP
been/VBN
identified/VBN
,/,
and/CC
the/DT
etiology/NN
causing/VBG
diabetes/NNS
has/VBZ
been/VBN
reasonably/RB
well/RB
studied/VBN
./.
====================
But/CC
,/,
there/EX
is/VBZ
still/RB
a/DT
gap/JJ
in/IN
deciding/VBG
on/IN
the/DT
choice/NN
of/IN
a/DT
drug/NN
,/,
especially/RB
when/WRB
the/DT
target/NN
is/VBZ
mutated/VBN
./.
====================
Mutations/NNS
in/IN
the/DT
KCNJ11/NN
gene/NN
,/,
encoding/VBG
the/DT
kir6.2/NN
channel/NN
,/,
are/VBP
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
congenital/JJ
hyperinsulinism/NN
,/,
having/VBG
a/DT
major/JJ
impact/NN
in/IN
causing/VBG
type/NN
1/CD
diabetes/VBZ
,/,
and/CC
due/JJ
to/TO
the/DT
lack/NN
of/IN
its/PRP$
3D/NN
structure/NN
,/,
an/DT
attempt/NN
has/VBZ
been/VBN
made/VBN
to/TO
predict/VB
the/DT
structure/NN
of/IN
kir6.2/NN
,/,
applying/VBG
fold/JJ
recognition/NN
methods/NNS
./.
====================
The/DT
current/JJ
work/NN
is/VBZ
intended/VBN
to/TO
investigate/VB
the/DT
affinity/NN
of/IN
four/CD
phytochemicals/NNS
namely/RB
,/,
curcumin/NN
(/(
Curcuma/NN
longa/RB
)/)
,/,
genistein/NN
(/(
Genista/NNP
tinctoria/NNS
)/)
,/,
piperine/NN
(/(
Piper/NN
nigrum/NN
)/)
,/,
and/CC
pterostilbene/NN
(/(
Vitis/NN
vinifera/FW
)/)
in/IN
a/DT
normal/JJ
as/IN
well/RB
as/IN
in/IN
a/DT
mutant/JJ
kir6.2/NN
model/NN
by/IN
adopting/VBG
a/DT
molecular/JJ
docking/NN
methodology/NN
./.
====================
The/DT
phytochemicals/NNS
were/VBD
docked/VBN
in/IN
both/CC
wild/JJ
and/CC
mutated/VBN
kir6.2/NN
models/NNS
in/IN
two/CD
rounds/NNS
:/:
blind/CC
docking/NN
followed/VBN
by/IN
ATP-binding/VBG
pocket-specific/JJ
docking/NN
./.
====================
From/IN
the/DT
binding/NN
pockets/NNS
,/,
the/DT
common/JJ
interacting/VBG
amino/NN
acid/NN
residues/NNS
participating/VBG
strongly/RB
within/IN
the/DT
binding/NN
pocket/NN
were/VBD
identified/VBN
and/CC
compared/VBN
./.
====================
From/IN
the/DT
study/NN
,/,
we/PRP
conclude/VBP
that/IN
these/DT
phytochemicals/NNS
have/VBP
strong/JJ
affinity/NN
in/IN
both/CC
the/DT
normal/JJ
and/CC
mutant/JJ
kir6.2/NN
model/NN
./.
====================
This/DT
work/NN
would/MD
be/VB
helpful/JJ
for/IN
further/JJ
study/NN
of/IN
the/DT
phytochemicals/NNS
above/JJ
for/IN
the/DT
treatment/NN
of/IN
type/NN
1/CD
diabetes/VBZ
by/IN
targeting/VBG
the/DT
kir6.2/NN
channel/NN
./.
====================
Type/NN
1/CD
and/CC
type/NN
2/CD
diabetes/NNS
mellitus/NN
is/VBZ
a/DT
major/JJ
health/NN
problem/NN
worldwide/NN
./.
====================
In/IN
case/NN
of/IN
type/NN
1/CD
diabetes/VBZ
,/,
the/DT
body/NN
is/VBZ
unable/JJ
to/TO
produce/VB
insulin/NN
due/JJ
to/TO
the/DT
autoimmune/JJ
destruction/NN
of/IN
the/DT
beta-cells/NNS
in/IN
the/DT
pancreas/NN
[/(
1/CD
]/)
,/,
and/CC
insulin/NN
injection/NN
is/VBZ
the/DT
only/RB
known/VBN
preventive/JJ
measure/VB
in/IN
this/DT
case/NN
[/(
2/CD
]/)
./.
====================
Most/JJS
of/IN
the/DT
anti-diabetic/JJ
drugs/NNS
of/IN
synthetic/JJ
origin/NN
have/VBP
serious/JJ
adverse/JJ
effects/NNS
;/:
therefore/RB
,/,
phytochemicals/NNS
and/CC
plant/JJ
extracts/NNS
with/IN
anti-diabetic/JJ
properties/NNS
have/VBP
been/VBN
tested/VBN
both/CC
in/FW
vivo/FW
and/CC
in/IN
vitro/FW
as/IN
alternatives/VBZ
for/IN
diabetic/JJ
treatments/NNS
[/(
3/CD
]/)
./.
====================
Phytochemicals/NNS
,/,
such/JJ
as/IN
curcumin/NN
(/(
Curcuma/NN
longa/RB
)/)
,/,
genistein/NN
(/(
Genista/NN
tinctoria/NN
)/)
,/,
piperine/NN
(/(
Piper/NN
nigrum/NN
)/)
,/,
and/CC
pterostilbene/NN
(/(
Vitis/NN
vinifera/NN
)/)
,/,
are/VBP
reported/VBN
to/TO
have/VB
potent/JJ
anti-diabetic/JJ
properties/NNS
./.
====================
Curcumin/NN
,/,
when/WRB
tested/VBN
in/IN
diabetic/JJ
animals/NNS
,/,
exhibited/VBD
a/DT
good/JJ
sign/NN
for/IN
the/DT
prevention/NN
and/CC
treatment/NN
of/IN
diabetic/JJ
encephalopathy/NN
[/(
4/CD
]/)
./.
====================
Genistein/NN
also/RB
plays/VBZ
important/JJ
roles/NNS
in/IN
the/DT
regulation/NN
of/IN
glucose/NN
homeostasis/NN
in/IN
type/NN
1/CD
diabetes/VBZ
by/IN
down-regulating/VBG
G6Pase/NN
,/,
PEPCK/NN
,/,
fatty/JJ
acid/NN
β-oxidation/NN
,/,
and/CC
carnitine/JJ
palmitoyl/NN
transferase/NN
activities/NNS
while/IN
up-regulating/VBG
malic/JJ
enzyme/NN
and/CC
glucose-6-phosphate-dehydrogenase/NN
activities/NNS
in/IN
the/DT
liver/NN
,/,
with/IN
preservation/NN
of/IN
pancreatic/JJ
β-cells/NNS
./.
====================
The/DT
supplementation/NN
of/IN
genistein/NN
is/VBZ
helpful/JJ
for/IN
preventing/VBG
insulin-dependent/JJ
diabetes/NNS
mellitus/NN
onset/NN
[/(
5/CD
]/)
and/CC
piperine/NN
,/,
an/DT
alkaloid/NN
,/,
has/VBZ
also/RB
been/VBN
reported/VBN
to/TO
possess/VB
potential/JJ
anti-diabetic/JJ
effects/NNS
[/(
6/CD
]/)
./.
====================
Experimental/JJ
results/NNS
suggested/VBD
the/DT
antiglycemic/JJ
effects/NNS
of/IN
pterostilbene/NN
in/IN
an/DT
induced/VBN
rat/NN
model/NN
of/IN
hyperglycemia/NN
./.
====================
Therefore/RB
,/,
the/DT
antioxidant/JJ
and/CC
antihyperglycemic/JJ
activities/NNS
of/IN
pterostilbene/NN
may/MD
confer/VB
a/DT
protective/JJ
effect/NN
in/IN
preventing/VBG
diabetes/NNS
[/(
7/CD
]/)
./.
====================
Several/JJ
receptors/NNS
(/(
insulin-like/JJ
growth/NN
factor/NN
receptor/NN
,/,
glucose/NN
transporter/NN
,/,
and/CC
kir6.2/NN
)/)
and/CC
their/PRP$
associated/VBN
signaling/NN
pathways/NNS
have/VBP
been/VBN
elucidated/VBN
and/CC
are/VBP
involved/VBN
in/IN
glucose/NN
regulation/NN
and/CC
diabetes/VBZ
./.
====================
But/CC
,/,
a/DT
significant/JJ
gap/NN
still/RB
remains/VBZ
as/IN
to/TO
making/VBG
the/DT
choice/NN
of/IN
the/DT
drug/NN
against/IN
the/DT
target/NN
receptor/NN
in/IN
the/DT
disease/NN
condition/NN
./.
====================
Kir6.2/NN
,/,
a/DT
major/JJ
subunit/NN
of/IN
the/DT
ATP-sensitive/JJ
K+/JJ
channel/NN
,/,
an/DT
inward-rectifying/VBG
potassium/NN
ion/NN
channel/NN
,/,
is/VBZ
an/DT
integral/JJ
membrane/NN
protein/NN
that/WDT
allows/VBZ
K+/JJ
to/TO
flow/NN
from/IN
the/DT
outside/IN
of/IN
the/DT
cell/NN
to/TO
the/DT
inside/NN
,/,
which/WDT
is/VBZ
controlled/VBN
by/IN
G-proteins/NNS
associated/VBN
with/IN
sulfonylurea/NN
receptor/NN
(/(
SUR/NN
)/)
,/,
to/TO
constitute/VB
the/DT
ATP-sensitive/JJ
K+/JJ
channel/NN
./.
====================
During/IN
glycolysis/NN
,/,
an/DT
increase/NN
in/IN
the/DT
ATP/ADP/NN
ratio/NN
blocks/VBZ
KATP/NN
channels/NNS
,/,
causing/VBG
membrane/NN
depolarization/NN
,/,
and/CC
helps/VBZ
in/IN
opening/VBG
the/DT
voltage-dependent/JJ
calcium/NN
channel/NN
,/,
which/WDT
facilitates/VBZ
the/DT
influx/NN
of/IN
calcium/NN
,/,
triggering/VBG
the/DT
exocytosis/NN
of/IN
insulin/NN
./.
====================
Mutations/NNS
in/IN
the/DT
two/CD
subunits/NNS
of/IN
SUR1/NN
and/CC
kir6.2/NN
result/NN
in/IN
the/DT
opening/VBG
of/IN
the/DT
pancreatic/JJ
KATP/NN
channel/NN
and/CC
permanent/JJ
closing/VBG
of/IN
the/DT
calcium/NN
channel/NN
,/,
thus/RB
blocking/VBG
insulin/NN
exocytosis/NN
./.
====================
Mutations/NNS
in/IN
KCNJ11/NN
,/,
the/DT
gene/NN
encoding/VBG
the/DT
channel/NN
,/,
are/VBP
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
congenital/JJ
hyperinsulinism/NN
[/(
8/CD
,/,
9/CD
]/)
./.
====================
Ten/CD
possible/JJ
mutations/NNS
affecting/VBG
the/DT
regular/JJ
mechanism/NN
of/IN
kir6.2/NN
[/(
8/CD
,/,
10/CD
,/,
11/CD
]/)
have/VBP
been/VBN
identified/VBN
as/IN
probable/JJ
causes/VBZ
of/IN
type/NN
1/CD
diabetes/VBZ
./.
====================
Due/IN
to/TO
the/DT
unavailability/NN
of/IN
the/DT
crystal/JJ
structure/NN
of/IN
kir6.2/NN
protein/NN
,/,
an/DT
attempt/NN
was/VBD
made/VBN
here/RB
to/TO
predict/VB
both/CC
the/DT
secondary/JJ
and/CC
tertiary/JJ
structures/NNS
using/VBG
in/IN
silico/NN
approach/NN
./.
====================
The/DT
objective/NN
of/IN
the/DT
current/JJ
investigation/NN
is/VBZ
to/TO
describe/VB
atomic/JJ
interactions/NNS
and/CC
the/DT
inhibitory/JJ
effect/NN
between/IN
both/CC
wild-type/JJ
and/CC
mutant/JJ
models/NNS
of/IN
kir6.2/NN
with/IN
phytochemicals/NNS
,/,
such/JJ
as/IN
curcumin/NN
,/,
genistein/NN
,/,
piperine/NN
,/,
and/CC
pterostilbene/NN
,/,
computationally/RB
./.
====================
Structure/NN
prediction/NN
and/CC
model/NN
validation/NN
of/IN
kir6.2/NN
(/(
wild/JJ
,/,
mutant/JJ
)/)
====================
The/DT
primary/JJ
sequence/NN
of/IN
kir6.2/NN
(/(
entry/NN
name/NN
,/,
KCNJ11_HUMAN/NN
)/)
was/VBD
retrieved/VBN
from/IN
SWISS-PROT/UniProt/JJ
KB/NN
(/(
ID/NN
,/,
Q14654/NN
)/)
./.
====================
The/DT
secondary/JJ
structure/NN
of/IN
both/DT
wild-type/JJ
and/CC
mutant/JJ
kir6.2/NN
was/VBD
predicted/VBN
using/VBG
Discovery/NN
Studio/NN
3.5/CD
./.
====================
The/DT
tertiary/JJ
structure/NN
prediction/NN
for/IN
kir6.2/NN
models/NNS
(/(
both/CC
wild/JJ
type/NN
and/CC
mutant/JJ
)/)
were/VBD
performed/VBN
using/VBG
the/DT
protein/NN
fold/JJ
recognition/NN
server/RB
Phyre2/NN
(/(
http/NN
:/:
//www.sbg.bio.ic.ac.uk/phyre2//JJ
)/)
with/IN
100/CD
%/NN
confidence/NN
./.
====================
The/DT
predicted/VBN
models/NNS
were/VBD
energetically/RB
minimized/VBN
in/IN
ModRefiner/JJ
(/(
http/NN
:/:
//zhanglab.ccmb.umich.edu/ModRefiner//JJ
)/)
to/TO
draw/VB
the/DT
initial/JJ
starting/VBG
models/NNS
closer/RB
to/TO
their/PRP$
native/JJ
state/NN
,/,
in/IN
terms/NNS
of/IN
hydrogen/NN
bonds/NNS
,/,
backbone/RB
topology/NN
,/,
and/CC
side/JJ
chain/NN
positioning/VBG
./.
====================
The/DT
coordinates/NNS
of/IN
the/DT
predicted/VBN
model/NN
of/IN
kir6.2/NN
were/VBD
submitted/VBN
in/IN
Protein/NN
Model/NN
DataBase/NN
(/(
http/NN
:/:
//bioinformatics.cineca.it/PMDB//JJ
)/)
./.
====================
Structural/JJ
validation/NN
was/VBD
done/VBN
in/IN
Procheck/NN
and/CC
Errat2/NN
of/IN
the/DT
Saves/NNS
web/NN
server/RB
(/(
http/NN
:/:
//nihserver.mbi.ucla.edu/SAVES_3//JJ
)/)
./.
====================
Protein/NN
model/NN
quality/NN
was/VBD
checked/VBN
in/IN
the/DT
protein/NN
structure/NN
analysis/NN
tool/NN
ProSA/NN
(/(
http/NN
:/:
//prosa.services.came.sbg.ac.at/prosa.php/JJ
)/)
./.
====================
Energetically/RB
minimized/VBN
structures/NNS
of/IN
both/DT
kir6.2/NN
models/NNS
were/VBD
visualized/VBN
and/CC
superimposed/VBD
in/IN
Discovery/NN
Studio/NN
3.5/CD
./.
====================
Molecular/JJ
docking/NN
of/IN
kir6.2/NN
model/NN
with/IN
phytochemicals/NNS
====================
Molecular/JJ
docking/NN
between/IN
kir6.2/NN
models/NNS
and/CC
phytochemicals/NNS
was/VBD
accomplished/VBN
using/VBG
the/DT
AutoDock-4.2/NN
algorithm/NN
(/(
http/NN
:/:
//autodock.scripps.edu//JJ
)/)
./.
====================
Kollman/JJ
united/JJ
atom/IN
charges/NNS
,/,
solvation/JJ
parameters/NNS
,/,
and/CC
polar/JJ
hydrogens/NNS
were/VBD
added/VBN
into/IN
the/DT
kir6.2/NN
PDB/NN
files/NNS
for/IN
the/DT
preparation/NN
of/IN
the/DT
protein/NN
in/IN
the/DT
docking/NN
simulation/NN
./.
====================
Chemical/JJ
structures/NNS
of/IN
phytochemicals/NNS
having/VBG
anti-diabetic/JJ
properties/NNS
were/VBD
extracted/VBN
from/IN
the/DT
Pubchem/JJ
(/(
http/NN
:/:
//ncbi.nlm.nih.gov/pccompound/JJ
)/)
database/NN
of/IN
the/DT
National/JJ
Center/NN
of/IN
Biotechnology/NN
Information/NN
(/(
NCBI/NN
)/)
web/NN
server/RB
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
in/IN
SDF/NN
format/IN
and/CC
converted/VBD
to/TO
three-dimensional/JJ
structures/NNS
in/IN
PDB/NN
format/IN
using/VBG
Discovery/NN
Studio/NN
3.5/CD
./.
====================
Ligand/NN
molecules/NNS
were/VBD
prepared/VBN
by/IN
choosing/VBG
the/DT
root/NN
and/CC
restricting/VBG
the/DT
number/NN
of/IN
torsion/NN
within/IN
a/DT
minimum/JJ
range/NN
./.
====================
AutoDock/NN
requires/VBZ
precalculated/JJ
grid/JJ
maps/VBZ
,/,
one/CD
for/IN
each/DT
atom/IN
type/NN
present/JJ
in/IN
the/DT
flexible/JJ
molecules/NNS
being/VBG
docked/VBN
,/,
and/CC
it/PRP
stores/NNS
the/DT
potential/JJ
energy/NN
arising/VBG
from/IN
the/DT
interaction/NN
with/IN
rigid/JJ
macromolecules/NNS
./.
====================
One/CD
hundred/VBD
runs/NNS
of/IN
blind/JJ
dockings/VBZ
were/VBD
performed/VBN
for/IN
all/DT
inhibitors/NNS
with/IN
both/CC
the/DT
wild-type/JJ
and/CC
mutant/JJ
protein/NN
model/NN
of/IN
kir6.2/NN
./.
====================
Then/RB
next/RB
round/NN
of/IN
docking/VBG
was/VBD
performed/VBN
by/IN
setting/VBG
a/DT
grid/JJ
of/IN
98/CD
,/,
100/CD
,/,
and/CC
62/CD
points/NNS
in/IN
the/DT
x/NN
,/,
y/RB
,/,
and/CC
z/NN
directions/NNS
,/,
respectively/RB
,/,
in/IN
the/DT
ATP-binding/JJ
site/NN
of/IN
kir6.2/NN
[/(
12/CD
]/)
for/IN
both/DT
models/NNS
by/IN
applying/VBG
the/DT
Lamarckian/JJ
genetic/JJ
algorithm/NN
./.
====================
The/DT
best/JJS
poses/VBZ
of/IN
docking/NN
during/IN
both/CC
rounds/NNS
were/VBD
compared/VBN
and/CC
reported/VBD
with/IN
the/DT
binding/NN
energy/NN
reported/VBD
for/IN
each/DT
case/NN
./.
====================
The/DT
visualization/NN
and/CC
analysis/NN
were/VBD
performed/VBN
using/VBG
Discover/NN
Studio/NN
3.5/CD
package/NN
./.
====================
Structure/NN
prediction/NN
and/CC
validation/NN
of/IN
kir6.2/NN
structural/JJ
models/NNS
====================
The/DT
primary/JJ
sequence/NN
of/IN
kir6.2/NN
(/(
UniProt/JJ
ID/NN
,/,
Q14654/NN
)/)
is/VBZ
a/DT
transmembrane/JJ
protein/NN
with/IN
390/CD
amino/NN
acid/NN
residues/NNS
./.
====================
Ten/CD
mutations/NNS
[/(
10/CD
]/)
were/VBD
introduced/VBN
in/IN
the/DT
primary/JJ
sequence/NN
of/IN
kir6.2/NN
for/IN
mutant/JJ
model/NN
prediction/NN
purposes/NNS
./.
====================
Two/CD
tertiary/JJ
structural/JJ
models/NNS
were/VBD
predicted/VBN
for/IN
both/DT
wild/JJ
(/(
template/NN
PDB/NN
ID/NN
,/,
3JYC/NN
)/)
and/CC
mutant-type/JJ
kir6.2/NN
(/(
template/NN
PDB/NN
ID/NN
,/,
3SYA/NN
)/)
separately/RB
using/VBG
Phyre2/NN
[/(
13/CD
]/)
with/IN
100/CD
%/NN
confidence/NN
,/,
followed/VBN
by/IN
energy/NN
minimization/NN
using/VBG
ModRefiner/JJ
[/(
14/CD
]/)
web/NN
server/RB
./.
====================
The/DT
structural/JJ
model/NN
of/IN
kir6.2/NN
is/VBZ
publically/RB
available/JJ
in/IN
the/DT
Protein/NN
Model/NN
DataBase/NN
(/(
PMID/NN
ID/NN
,/,
PM0079770/NN
)/)
./.
====================
The/DT
quality/NN
of/IN
the/DT
model/NN
was/VBD
compared/VBN
with/IN
three/CD
existing/VBG
models/NNS
of/IN
kir6.2/NN
available/JJ
in/IN
the/DT
Protein/NN
Model/NN
Portal/JJ
(/(
http/NN
:/:
//www.proteinmodelportal.org/query/uniprot/Q14654/CD
)/)
./.
====================
The/DT
first/JJ
model/NN
available/JJ
in/IN
the/DT
Protein/NN
Model/NN
Portal/JJ
was/VBD
done/VBN
for/IN
the/DT
amino/NN
acid/NN
region/NN
of/IN
179-351/CD
,/,
taking/VBG
template/NN
PDB/NN
ID/NN
1U4F/NN
,/,
chain/NN
C/NN
with/IN
a/DT
53/CD
%/NN
identity/NN
score/RB
./.
====================
However/RB
,/,
this/DT
model/NN
is/VBZ
not/RB
complete/JJ
in/IN
comparison/NN
to/TO
the/DT
present/JJ
predicted/VBN
model/NN
of/IN
kir6.2/NN
(/(
PMID/NN
,/,
PM0079770/NN
)/)
,/,
which/WDT
is/VBZ
modeled/VBN
from/IN
amino/NN
acid/NN
region/NN
33-358/CD
./.
====================
The/DT
second/JJ
and/CC
third/JJ
models/NNS
available/JJ
are/VBP
almost/RB
complete/JJ
and/CC
modeled/JJ
for/IN
the/DT
same/JJ
amino/NN
acid/NN
region/NN
as/IN
in/IN
the/DT
present/JJ
model/NN
of/IN
wild/JJ
kir6.2/NN
./.
====================
While/IN
comparing/VBG
the/DT
quality/NN
with/IN
all/DT
experimentally/RB
determined/VBN
protein/NN
chains/NNS
in/IN
the/DT
current/JJ
PDB/NN
using/VBG
the/DT
ProSA/NN
web/NN
server/RB
[/(
15/CD
]/)
by/IN
means/NNS
of/IN
a/DT
significant/JJ
statistical/JJ
score/RB
(/(
z-score/RB
)/)
in/IN
terms/NNS
of/IN
folding/VBG
energy/NN
,/,
the/DT
second/JJ
and/CC
third/JJ
models/NNS
had/VBD
a/DT
z-score/RB
computed/VBN
in/IN
the/DT
ProSA/NN
web/NN
server/RB
of/IN
-5.16/CD
(/(
Supplementary/JJ
Fig/NN
./.
====================
2B/NN
)/)
and/CC
-5.6/CD
(/(
Supplementary/NN
Fig/NN
./.
====================
2C/NN
)/)
,/,
respectively/RB
,/,
while/IN
in/IN
comparison/NN
,/,
the/DT
current/JJ
model/NN
had/VBD
a/DT
good/JJ
folding/VBG
energy/NN
score-i.e./FW
,/,
z-score/RB
of/IN
-5.96/CD
(/(
Supplementary/JJ
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
The/DT
overall/JJ
quality/NN
factors/NNS
of/IN
these/DT
two/CD
models/NNS
were/VBD
also/RB
compared/VBD
with/IN
the/DT
current/JJ
predicted/VBN
model/NN
of/IN
kir6.2/NN
using/VBG
Errat2/NN
./.
====================
The/DT
overall/JJ
quality/NN
factor/NN
for/IN
the/DT
second/JJ
and/CC
third/JJ
models/NNS
deposited/VBN
in/IN
the/DT
Protein/NN
Model/NN
Portal/JJ
was/VBD
computed/VBN
to/TO
be/VB
69.132/CD
(/(
Supplementary/JJ
Fig/NN
./.
====================
3B/NN
)/)
and/CC
67.508/CD
(/(
Supplementary/NN
Fig/NN
./.
====================
3C/NN
)/)
,/,
respectively/RB
,/,
which/WDT
is/VBZ
quite/RB
poor/JJ
in/IN
comparison/NN
to/TO
the/DT
quality/NN
score/RB
of/IN
78.778/CD
(/(
Supplementary/JJ
Fig/NN
./.
====================
3A/NN
)/)
computed/VBD
for/IN
the/DT
current/JJ
model/NN
of/IN
kir6.2/NN
(/(
PM0079770/NN
)/)
./.
====================
Again/RB
,/,
superimposition/NN
of/IN
the/DT
second/JJ
model/NN
(/(
blue/JJ
color/JJ
)/)
available/JJ
in/IN
Protein/NN
Model/NN
Portal/JJ
and/CC
the/DT
present/JJ
model/NN
of/IN
kir6.2/NN
(/(
red/JJ
color/JJ
)/)
also/RB
gives/VBZ
a/DT
clear-cut/JJ
idea/NN
of/IN
the/DT
quality/NN
of/IN
the/DT
model/NN
presented/VBN
here/RB
(/(
Supplementary/JJ
Fig/NN
./.
====================
4/CD
)/)
./.
====================
The/DT
quality/NN
of/IN
the/DT
backbone/NN
folding/VBG
pattern/NN
of/IN
the/DT
present/JJ
model/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
5A/CD
)/)
in/IN
comparison/NN
to/TO
the/DT
third/JJ
model/NN
available/JJ
in/IN
Protein/NN
Model/NN
Portal/JJ
(/(
Supplementary/JJ
Fig/NN
./.
====================
5B/NN
)/)
is/VBZ
also/RB
good/JJ
./.
====================
From/IN
the/DT
above/JJ
,/,
it/PRP
is/VBZ
found/VBN
that/IN
the/DT
model/NN
predicted/VBN
here/RB
for/IN
kir6.2/NN
is/VBZ
good/JJ
in/IN
comparison/NN
to/TO
all/DT
three/CD
existing/VBG
models/NNS
available/JJ
in/IN
Protein/NN
Model/NN
Portal/JJ
./.
====================
Structural/JJ
comparison/NN
of/IN
wild/JJ
and/CC
mutant/JJ
models/NNS
of/IN
kir6.2/NN
====================
Similarly/RB
,/,
by/IN
comparison/NN
of/IN
the/DT
wild/JJ
and/CC
mutant/JJ
models/NNS
of/IN
kir6.2/NN
,/,
the/DT
quality/NN
is/VBZ
confirmed/VBN
as/IN
good/JJ
for/IN
both/DT
predicted/VBN
models/NNS
of/IN
kir6.2/NN
,/,
because/IN
the/DT
values/NNS
of/IN
the/DT
computed/JJ
z-score/RB
of/IN
the/DT
computed/JJ
models/NNS
of/IN
kir6.2/NN
are/VBP
within/IN
the/DT
range/NN
of/IN
z-scores/NNS
of/IN
the/DT
groups/NNS
of/IN
structures/NNS
from/IN
different/JJ
sources/NNS
,/,
like/IN
X-ray/NN
and/CC
nuclear/JJ
magnetic/JJ
resonance/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
6/CD
)/)
./.
====================
The/DT
Ramachandran/NN
plot/NN
statistics/NNS
(/(
Supplementary/NN
Fig/NN
./.
====================
7/CD
)/)
show/VBP
93.8/CD
%/NN
of/IN
residues/NNS
in/IN
the/DT
most/JJS
favored/VBD
region/NN
in/IN
the/DT
case/NN
of/IN
the/DT
wild/JJ
kir6.2/NN
model/NN
,/,
whereas/IN
in/IN
the/DT
mutant/JJ
model/NN
,/,
92.8/CD
%/NN
of/IN
residues/NNS
are/VBP
found/VBN
in/IN
the/DT
same/JJ
region/NN
./.
====================
At/IN
the/DT
same/JJ
time/NN
,/,
no/DT
residues/NNS
were/VBD
found/VBN
in/IN
the/DT
disallowed/JJ
region/NN
in/IN
both/DT
the/DT
wild/JJ
and/CC
mutant/JJ
models/NNS
of/IN
kir6.2/NN
,/,
which/WDT
signified/VBD
the/DT
good/JJ
quality/NN
of/IN
the/DT
backbone/NN
folding/VBG
pattern/NN
in/IN
both/DT
models/NNS
./.
====================
The/DT
non-bonded/JJ
interactions/NNS
between/IN
different/JJ
atoms/NNS
were/VBD
plotted/VBN
residue-wise/RB
against/IN
error/JJ
function/NN
to/TO
calculate/JJ
the/DT
overall/JJ
quality/NN
factor/NN
of/IN
both/DT
models/NNS
in/IN
Errat2/NN
,/,
which/WDT
justified/VBD
the/DT
improvement/NN
in/IN
quality/NN
of/IN
kir6.2/NN
mutant/JJ
model/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
8/CD
)/)
./.
====================
The/DT
comparison/NN
of/IN
secondary/JJ
structural/JJ
elements/NNS
of/IN
both/DT
wild-type/JJ
and/CC
mutant/JJ
kir6.2/NN
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
reveals/VBZ
that/IN
there/EX
is/VBZ
an/DT
increment/JJ
in/IN
disordered/JJ
regions/NNS
in/IN
the/DT
mutant/JJ
model/NN
,/,
but/CC
there/EX
is/VBZ
no/DT
major/JJ
structural/JJ
deviation/NN
due/JJ
to/TO
the/DT
mutation/NN
introduced/VBD
at/IN
the/DT
sequence/NN
level/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
This/DT
is/VBZ
also/RB
supported/VBD
by/IN
the/DT
root/NN
mean/JJ
square/VBP
deviation/NN
of/IN
the/DT
main/JJ
chain/NN
at/IN
the/DT
tertiary/JJ
structural/JJ
level/NN
,/,
which/WDT
is/VBZ
computed/VBN
as/IN
0.854/CD
by/IN
superimposition/NN
of/IN
the/DT
structural/JJ
models/NNS
of/IN
both/DT
wild/JJ
and/CC
mutant/JJ
kir6.2/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Molecular/JJ
docking/NN
analysis/NN
of/IN
kir6.2/NN
model/NN
with/IN
phytochemicals/NNS
====================
The/DT
results/NNS
of/IN
molecular/JJ
docking/NN
between/IN
the/DT
wild-type/JJ
kir6.2/NN
model/NN
and/CC
all/DT
four/CD
phytochemicals/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
separately/RB
for/IN
100/CD
runs/NNS
(/(
blind/CC
docking/NN
)/)
and/CC
10/CD
runs/NNS
(/(
ATP-binding/JJ
site/NN
docking/NN
)/)
revealed/VBD
that/IN
phytochemicals/NNS
bind/VBP
favorably/RB
in/IN
the/DT
same/JJ
pocket/NN
of/IN
the/DT
wild/JJ
kir6.2/NN
model/NN
./.
====================
The/DT
same/JJ
observation/NN
was/VBD
found/VBN
in/IN
the/DT
case/NN
of/IN
the/DT
docking/NN
of/IN
the/DT
mutant/JJ
kir6.2/NN
model/NN
with/IN
the/DT
same/JJ
phytochemicals/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
,/,
which/WDT
supports/VBZ
the/DT
prediction/NN
of/IN
the/DT
pocket/NN
as/IN
an/DT
active/JJ
binding/NN
region/NN
for/IN
phytochemicals/NNS
./.
====================
The/DT
best/JJS
docked/VBD
poses/VBZ
found/VBN
in/IN
energetically/RB
favorable/JJ
binding/NN
conditions/NNS
with/IN
phytochemicals/NNS
are/VBP
reported/VBN
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
The/DT
comparative/JJ
data/NNS
of/IN
interacting/VBG
residues/NNS
within/IN
4/CD
Å/NN
in/IN
both/CC
the/DT
wild/JJ
and/CC
mutant/JJ
kir6.2/NN
predicted/VBN
models/NNS
are/VBP
reported/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
hydrophobic/JJ
amino/NN
acids/NNS
Ala-178/NN
,/,
Leu-181/NNP
,/,
Phe-183/NN
,/,
and/CC
Ala-300/NN
are/VBP
found/VBN
within/IN
the/DT
pocket/NN
,/,
providing/VBG
stability/NN
towards/IN
the/DT
binding/NN
of/IN
phytochemicals/NNS
with/IN
the/DT
kir6.2/NN
models/NNS
./.
====================
The/DT
interacting/VBG
residues/NNS
of/IN
the/DT
mutant/JJ
kir6.2/NN
model/NN
are/VBP
deciphered/VBN
in/IN
Fig/NN
./.
====================
3/CD
,/,
along/IN
with/IN
hydrogen/NN
bond/NN
interactions/NNS
within/IN
3.5/CD
Å/NN
of/IN
distance/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
As/IN
per/IN
the/DT
information/NN
in/IN
Table/JJ
2/CD
,/,
the/DT
amino/NN
acids/NNS
Phe-183/NN
and/CC
Arg-301/NN
have/VBP
common/JJ
involvement/NN
in/IN
hydrogen/NN
bonding/VBG
in/IN
the/DT
mutant/JJ
model/NN
of/IN
the/DT
kir6.2/NN
protein/NN
with/IN
curcumin/NN
,/,
genistein/NN
,/,
piperine/NN
,/,
and/CC
pterostilbene/NN
,/,
suggesting/VBG
strong/JJ
binding/VBG
affinity/NN
in/IN
the/DT
predicted/VBN
binding/VBG
pocket/NN
./.
====================
It/PRP
is/VBZ
a/DT
well-established/JJ
fact/NN
that/IN
the/DT
main/JJ
cause/JJ
of/IN
type/NN
1/CD
diabetes/VBZ
is/VBZ
the/DT
autoimmune/JJ
destruction/NN
of/IN
β-cells/NNS
in/IN
the/DT
pancreas/NN
[/(
1/CD
]/)
./.
====================
Reports/NNS
demonstrate/VBP
that/IN
kir6.2/NN
is/VBZ
an/DT
ATP/ADP/NN
ratio-sensitive/JJ
protein/NN
that/WDT
plays/VBZ
a/DT
vital/JJ
role/NN
in/IN
operating/VBG
the/DT
K+/JJ
channel/NN
and/CC
simultaneously/RB
controls/VBZ
Ca+2/NN
ion/NN
channel/NN
function/NN
,/,
which/WDT
in/IN
turn/NN
triggers/VBZ
the/DT
exocytosis/NN
of/IN
insulin/NN
./.
====================
But/CC
,/,
due/JJ
to/TO
mutations/NNS
[/(
10/CD
]/)
in/IN
certain/JJ
amino/NN
acids/NNS
(/(
H46Y/NN
,/,
R50Q/NNP
,/,
Q52R/NN
,/,
G53D/NNP
,/,
V59M/NNP
,/,
L164P/NN
,/,
C166T/NN
,/,
K170T/NN
,/,
R201H/NN
,/,
and/CC
Y330S/NN
)/)
,/,
the/DT
whole/JJ
mechanism/NN
is/VBZ
perturbed/VBN
,/,
blocking/VBG
the/DT
exocytosis/NN
of/IN
insulin/NN
,/,
which/WDT
might/MD
be/VB
a/DT
cause/JJ
of/IN
type-1/NN
diabetes/VBZ
./.
====================
Again/RB
,/,
due/JJ
to/TO
the/DT
unavailability/NN
of/IN
the/DT
crystal/JJ
structure/NN
of/IN
kir6.2/NN
,/,
molecular/JJ
targeting/VBG
with/IN
drugs/NNS
is/VBZ
difficult/JJ
./.
====================
But/CC
,/,
a/DT
rational/JJ
design/NN
of/IN
in/FW
silico/NN
structure/NN
prediction/NN
approaches/NNS
comes/VBZ
in/IN
handy/NN
under/IN
such/JJ
circumstances/NNS
to/TO
study/VB
this/DT
further/JJ
./.
====================
From/IN
the/DT
structural/JJ
inspection/NN
of/IN
both/DT
wild-type/JJ
and/CC
mutant/JJ
kir6.2/NN
models/NNS
,/,
it/PRP
is/VBZ
concluded/VBN
that/IN
mutation/NN
has/VBZ
no/DT
major/JJ
structural/JJ
changes/NNS
or/CC
deviation/NN
in/IN
the/DT
structure/NN
quality/NN
of/IN
the/DT
model/NN
./.
====================
In/IN
recent/JJ
years/NNS
,/,
due/JJ
to/TO
the/DT
adverse/JJ
effect/NN
of/IN
synthetic/JJ
drugs/NNS
,/,
phytochemicals/NNS
have/VBP
drawn/VBN
substantial/JJ
attention/NN
as/IN
alternative/JJ
medications/NNS
./.
====================
The/DT
literature/NN
reports/NNS
curcumin/NN
,/,
genistein/NN
,/,
piperine/NN
,/,
and/CC
pterostilbene/NN
to/TO
have/VB
strong/JJ
inhibitory/JJ
effects/NNS
against/IN
type/NN
1/CD
diabetes/VBZ
./.
====================
Hence/RB
,/,
all/DT
four/CD
of/IN
these/DT
phytochemicals/NNS
were/VBD
docked/VBN
with/IN
predicted/VBN
models/NNS
of/IN
kir6.2/NN
in/IN
the/DT
ATP-binding/JJ
pocket/NN
[/(
12/CD
]/)
to/TO
check/VB
the/DT
inhibitory/JJ
effect/NN
after/IN
mutation/NN
./.
====================
The/DT
results/NNS
of/IN
docking/NN
suggested/VBD
that/IN
all/DT
phytochemicals/NNS
bind/VBP
at/IN
high/JJ
affinity/NN
with/IN
both/DT
models/NNS
,/,
and/CC
the/DT
common/JJ
interacting/VBG
residues/NNS
Ala-178/NN
,/,
Leu-181/NNP
,/,
Phe-183/NN
,/,
and/CC
Ala-300/NN
were/VBD
found/VBN
in/IN
the/DT
same/JJ
pocket/NN
,/,
even/RB
after/IN
mutation/NN
./.
====================
Amino/DT
acid/NN
residues/NNS
,/,
like/IN
Phe-183/NN
and/CC
Arg-301/NN
,/,
have/VBP
also/RB
been/VBN
observed/VBN
as/IN
participating/VBG
in/IN
hydrogen/NN
bonding/VBG
within/IN
the/DT
binding/VBG
pocket/NN
of/IN
mutant/JJ
kir6.2/NN
in/IN
the/DT
case/NN
of/IN
docking/VBG
with/IN
all/DT
four/CD
inhibitors/NNS
,/,
supporting/VBG
the/DT
fact/NN
that/IN
mutation/NN
might/MD
not/RB
affect/VB
the/DT
binding/VBG
affinity/NN
of/IN
kir6.2/NN
protein/NN
with/IN
phytochemicals/NNS
./.
====================
The/DT
current/JJ
investigation/NN
concluded/VBD
that/IN
phytochemicals/NNS
,/,
like/IN
curcumin/NN
,/,
genistein/NN
,/,
piperine/NN
,/,
and/CC
pterostilbene/NN
,/,
have/VBP
strong/JJ
inhibitory/JJ
effects/NNS
on/IN
kir6.2/NN
protein/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
study/NN
reports/VBZ
that/IN
these/DT
four/CD
phytochemicals/NNS
namely/RB
,/,
curcumin/NN
,/,
genistein/NN
,/,
piperine/NN
,/,
and/CC
pterostilbene/NN
are/VBP
effective/JJ
in/IN
both/DT
normal/JJ
and/CC
mutant/JJ
conditions/NNS
of/IN
kir6.2/NN
,/,
suggesting/VBG
future/JJ
implications/NNS
for/IN
type/NN
1/CD
diabetes/VBZ
mellitus/NN
treatment/NN
./.
====================
Comparison/NN
of/IN
predicted/VBN
secondary/JJ
structures/NNS
in/IN
wild-type/JJ
(/(
kir6.2/CD
)/)
and/CC
mutant-type/JJ
(/(
mu_kir6.2/NN
)/)
model/NN
./.
====================
Alignment/JJ
done/NN
for/IN
amino/NN
acids/NNS
33-358/CD
of/IN
kir6.2/NN
models/NNS
./.
====================
Secondary/JJ
structural/JJ
element/NN
(/(
DSC/NN
)/)
helix/NN
is/VBZ
represented/VBN
by/IN
red/JJ
cylinder/NN
,/,
and/CC
beta/NN
sheets/NNS
are/VBP
represented/VBN
by/IN
blue/JJ
arrows/VBZ
in/IN
the/DT
picture/NN
./.
====================
Superimposition/NN
of/IN
predicted/VBN
tertiary/NN
models/NNS
of/IN
kir6.2/NN
wild-type/JJ
(/(
blue/JJ
color/JJ
)/)
and/CC
mutant/JJ
(/(
red/JJ
color/NN
)/)
./.
====================
The/DT
mutation/NN
position/NN
,/,
along/IN
with/IN
amino/NN
acid/NN
residues/NNS
,/,
is/VBZ
mentioned/VBN
in/IN
the/DT
picture/NN
./.
====================
Atomic/JJ
interaction/NN
shown/VBN
between/IN
phytochemicals/NNS
curcumin/NN
(/(
A/DT
)/)
,/,
genistein/NN
(/(
B/NN
)/)
,/,
piperine/NN
(/(
C/NN
)/)
,/,
and/CC
pterostilbene/NN
(/(
D/NN
)/)
with/IN
mutant/JJ
kir6.2/NN
model/NN
within/IN
the/DT
binding/NN
pocket/NN
./.
====================
Hydrogen/NN
bond/NN
interactions/NNS
within/IN
3.5/CD
Å/NN
are/VBP
presented/VBN
in/IN
dotted/JJ
lines/NNS
in/IN
the/DT
pictures/NNS
./.
====================
Hydrophobic/JJ
amino/NN
acid/NN
residues/NNS
of/IN
kir6.2/NN
models/NNS
(/(
wild-type/JJ
and/CC
mutant/JJ
)/)
participating/VBG
in/IN
binding/VBG
interaction/NN
within/IN
4/CD
Å/NN
within/IN
the/DT
binding/NN
pocket/NN
with/IN
phytochemicals/NNS
====================
Amino/DT
acid/NN
residues/NNS
participating/VBG
in/IN
hydrogen/NN
bond/NN
interaction/NN
in/IN
mutant-type/JJ
kir6.2/NN
model/NN
with/IN
all/DT
four/CD
phytochemicals/NNS
====================
